Canadian patented drug prices : gauging the change in reference countries. : YN5-258/2022E-PDF

"The Parliamentary Budget Officer (PBO) supports Parliament by providing economic and financial analysis for the purposes of raising the quality of parliamentary debate and promoting greater budget transparency and accountability. Regulatory changes for how the Patented Medicines Prices Review Board (PMPRB) formulates price ceilings for patented drugs have been proposed and are due to come into effect in July of 2022. This report examines the proposed change and quantifies its long-term impact. We find that a change to the median of eleven comparator countries is important, but that more flexibility to re-adjust prices would potentially contribute more to reducing expenditures by Canadians."

Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.917914&sl=1

• Format MARC XML
• Format MARC HTML

Demander des formats alternatifs